Ocular Therapeutix(OCUL) - 2023 Q1 - Earnings Call Transcript

To date, we have reported interim data at two time points, seven months and 10 months, and have not observed any drug-related ocular or systemic series adverse events in OTX-TKI treated subjects. Importantly, the 73% of the OTX-TKI activated subjects who were rescue-free at month seven interim analysis remain rescue-free at month 10, highlighting what we believe is best-in-class durability. The ease of use of an office-based injection and long-term durability could establish OTX-TKI is the first standard of ...